Aaron Pettit - Axonics Modulation General Officer
Executive
Aaron Pettit is General Officer of Axonics Modulation Technologies
| Phone | 949 396 6322 |
| Web | https://www.axonics.com |
Axonics Modulation Management Efficiency
Axonics Modulation's management efficiency ratios could be used to measure how well Axonics Modulation manages its routine affairs as well as how well it operates its assets and liabilities.Axonics Modulation Technologies currently holds 27.62 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Axonics Modulation has a current ratio of 10.28, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Axonics Modulation's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brent JD | Bruker | 49 | |
| Torod Neptune | Medtronic PLC | N/A | |
| Sarah Huber | Pulmonx Corp | N/A | |
| Tracy Founds | Glaukos Corp | N/A | |
| Daniel Wilson | iRhythm Technologies | 42 | |
| Richard Glaze | CONMED | 59 | |
| Jane Rady | Glaukos Corp | 76 | |
| Aimee Einstein | Si Bone | N/A | |
| Orit MD | Nano X Imaging | 54 | |
| Mathieu Aussermeier | Integra LifeSciences Holdings | N/A | |
| Stuart Hart | Integra LifeSciences Holdings | N/A | |
| Michele Allegretto | Glaukos Corp | N/A | |
| Kelley Nicholas | Neuropace | N/A | |
| Dylan John | Neuropace | N/A | |
| Martha MD | Neuropace | 68 | |
| Philip Kowalczyk | LivaNova PLC | N/A | |
| Kenneth Washington | Medtronic PLC | 65 | |
| Matthew III | LivaNova PLC | N/A | |
| Marcee Maroney | Pulmonx Corp | 55 | |
| Laurene Isip | Integra LifeSciences Holdings | N/A | |
| Amy Treadwell | Neuropace | N/A | |
Management Performance
| Return On Equity | -0.0089 | |||
| Return On Asset | -0.0063 |
Axonics Modulation Leadership Team
Elected by the shareholders, the Axonics Modulation's board of directors comprises two types of representatives: Axonics Modulation inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axonics. The board's role is to monitor Axonics Modulation's management team and ensure that shareholders' interests are well served. Axonics Modulation's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axonics Modulation's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alfred Ford, Chief Commercial Officer | ||
| Danny Dearen, Chief Operating and Financial Officer | ||
| MD MAS, Chief Officer | ||
| Raymond Cohen, CEO, Director | ||
| Rinda Sama, Chief Officer | ||
| JD Esq, General VP | ||
| Aaron Pettit, General Officer | ||
| Kari Keese, Chief Officer | ||
| John Woock, Chief Marketing Officer | ||
| Neil Bhalodkar, Vice Relations | ||
| Guangqiang Jiang, Chief Officer |
Axonics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axonics Modulation a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0089 | |||
| Return On Asset | -0.0063 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | (0.02) % | |||
| Current Valuation | 3.32 B | |||
| Shares Outstanding | 51.11 M | |||
| Shares Owned By Insiders | 1.26 % | |||
| Shares Owned By Institutions | 87.22 % | |||
| Number Of Shares Shorted | 3.31 M | |||
| Price To Earning | (10.68) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in Axonics Stock
If you are still planning to invest in Axonics Modulation check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Axonics Modulation's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |